Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Retransplantation for recurrent hepatitis C.

Rafik M Ghobrial1

  • 1Department of Surgery, Division of Liver and Pancreas Transplantation, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, USA. rghobria@mednet.ucla.edu

Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
|October 4, 2002
PubMed
Summary

Re-transplantation (re-OLT) for hepatitis C virus (HCV) recurrence after liver transplantation is necessary long-term. Early re-OLT in selected patients yields outcomes comparable to other re-OLT indications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetically modulating the RNA-binding protein Regnase-1 reveals its critical role in regulatory T cell homeostasis and function in vivo.

Cell death & disease·2026
Same author

Macrophages in Chronic Rejection: The Shapeshifters Behind Transplant Survival.

Biology·2026
Same author

CD8<sup>+</sup> T cell differentiation into NK-like effector cells drives transplant rejection.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Epigenetically modulating macrophage subpopulations to promote long-term allograft survival in a mouse heart transplant model.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2025
Same author

Apex1 safeguards genomic stability to ensure a cytopathic T cell fate in autoimmune disease models.

The Journal of clinical investigation·2024
Same author

Macrophage niche imprinting as a determinant of macrophage identity and function.

Cellular immunology·2024

Area of Science:

  • Hepatology
  • Transplantation Immunology
  • Virology

Background:

  • Primary orthotopic liver transplantation (OLT) for hepatitis C virus (HCV) infection demonstrates favorable outcomes.
  • Re-OLT in HCV-infected recipients is often for non-recurrent indications in the short term.

Purpose of the Study:

  • To evaluate the long-term necessity and outcomes of re-OLT for recurrent HCV infection post-liver transplantation.
  • To assess if outcomes of re-OLT for recurrent HCV differ from other re-OLT indications.

Main Methods:

  • Retrospective analysis of liver transplant recipients undergoing re-OLT.
  • Comparison of outcomes based on indication for re-OLT, specifically recurrent HCV versus other causes.
  • Evaluation of graft survival and patient survival rates.

Related Experiment Videos

Main Results:

  • Progressive allograft injury due to recurrent HCV infection drives the long-term need for re-OLT.
  • Outcomes of re-OLT for recurrent hepatitis C are equivalent to those for other re-OLT indications.
  • Early re-OLT in patients with recurrent HCV, before critical illness, leads to good outcomes.

Conclusions:

  • Recurrent hepatitis C is a significant long-term indication for re-OLT after primary liver transplantation.
  • Re-OLT for recurrent HCV can achieve outcomes comparable to other indications when performed strategically.
  • Timely intervention with re-OLT in selected HCV-infected liver transplant recipients is crucial for favorable results.